Sökning: "Rasch modelling"

Hittade 2 avhandlingar innehållade orden Rasch modelling.

  1. 1. Measuring health literacy : Evaluating psychometric properties of the HLS-EU-Q47 and the FCCHL, suggesting instrument refinements and exploring health literacy in people with type 2 diabetes and in the general Norwegian population

    Författare :Hanne Søberg Finbråten; Bodil Wilde-Larsson; Gun Nordström; Kjell Sverre Pettersen; Anne Trollvik; Øystein Guttersrud; Unn-Britt Johansson; Karlstads universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; confirmatory factor analysis; FCCHL; health literacy; health-promotion nursing; HLS-EU-Q47; HLS-N-Q12; measurement; Norwegian population; psychometric evaluation; Rasch modelling; type 2 diabetes; validation; FCCHL; health literacy; helsefremmende sykepleie; HLS-EU-Q47; HLS-N-Q12; konfirmatorisk faktor analyse; måling; norsk befolkning; personer med diabetes type 2; psykometrisk evaluering; Rasch modellering; validering; Nursing Science; Omvårdnad;

    Sammanfattning : Aim: The overall aim was to measure health literacy (HL) in people with type 2 diabetes (T2DM) and in the general Norwegian population.Methods: Sampling 388 people with T2DM (papers I, II and IV) and 900 individuals (III) in the general Norwegian population a cross-sectional design was applied. LÄS MER

  2. 2. The health economics of Duchenne muscular dystrophy

    Författare :Erik Landfeldt; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP;

    Sammanfattning : Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease characterized by progressive muscle degeneration resulting in loss of independent ambulation, serious multisystem complications, and a mean life expectancy at birth of about 25 years. Several therapies are on the horizon for DMD and it has thus become urgent to better understand the health economic context of the disease to enable assessments of cost-effectiveness and inform decisions regarding reimbursement of new health technologies. LÄS MER